Orchard Therapeutics PLC Sponsored ADR (ORTX)
(Delayed Data from NSDQ)
$20.25 USD
+0.55 (2.79%)
Updated May 3, 2019 04:00 PM ET
After-Market: $20.25 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ORTX 20.25 +0.55(2.79%)
Will ORTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ORTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ORTX
Strength Seen in Arvinas, Inc. (ARVN): Can Its 6.3% Jump Turn into More Strength?
Cytokinetics (CYTK) Soars 11.4%: Is Further Upside Left in the Stock?
ORTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin
Orchard Therapeutics PLC Sponsored ADR (ORTX) Surges 96.0%: Is This an Indication of Further Gains?
Intercept (ICPT) Stock Jumps 79.2%: Will It Continue to Soar?